Proton pump inhibitors: an update of their clinical use and pharmacokinetics
S Shi, U Klotz - European journal of clinical pharmacology, 2008 - Springer
Abstract Background Proton pump inhibitors (PPIs) represent drugs of first choice for treating
peptic ulcer, Helicobacter pylori infection, gastrooesophageal reflux disease, nonsteroidal …
peptic ulcer, Helicobacter pylori infection, gastrooesophageal reflux disease, nonsteroidal …
The pig as a preclinical model for predicting oral bioavailability and in vivo performance of pharmaceutical oral dosage forms: a PEARRL review
LJ Henze, NJ Koehl, JP O'Shea… - Journal of pharmacy …, 2019 - academic.oup.com
Objectives In pharmaceutical drug development, preclinical tests in animal models are
essential to demonstrate whether the new drug is orally bioavailable and to gain a first …
essential to demonstrate whether the new drug is orally bioavailable and to gain a first …
Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers
RM Baldwin, S Ohlsson, RS Pedersen… - British journal of …, 2008 - Wiley Online Library
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The only existing study of CYP2C19*
17‐associated alterations in drug pharmacokinetics was retrospective and compared probe …
17‐associated alterations in drug pharmacokinetics was retrospective and compared probe …
In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america …
V Chu, HJ Einolf, R Evers, G Kumar, D Moore… - Drug Metabolism and …, 2009 - ASPET
Cytochrome P450 (P450) induction is one of the factors that can affect the pharmacokinetics
of a drug molecule upon multiple dosing, and it can result in pharmacokinetic drug-drug …
of a drug molecule upon multiple dosing, and it can result in pharmacokinetic drug-drug …
Fluoxetine‐ and Norfluoxetine‐Mediated Complex Drug–Drug Interactions: In Vitro to In Vivo Correlation of Effects on CYP2D6, CYP2C19, and CYP3A4
JE Sager, JD Lutz, RS Foti, C Davis… - Clinical …, 2014 - Wiley Online Library
Fluoxetine and its circulating metabolite norfluoxetine comprise a complex multiple‐inhibitor
system that causes reversible or time‐dependent inhibition of the cytochrome P450 (CYP) …
system that causes reversible or time‐dependent inhibition of the cytochrome P450 (CYP) …
Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors
HJ Zhang, XH Zhang, J Liu, LN Sun, YW Shen… - Pharmacological …, 2020 - Elsevier
Proton pump inhibitors (PPIs) are used widely for the treatment of acid-related disorders.
Despite their excellent efficacy and tolerance, the pharmacodynamics and pharmacokinetics …
Despite their excellent efficacy and tolerance, the pharmacodynamics and pharmacokinetics …
Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using …
Understanding the influence of ethnicity on drug exposure is key to patient safety and could
minimize repetitive clinical studies. This analysis aimed to evaluate the ability of …
minimize repetitive clinical studies. This analysis aimed to evaluate the ability of …
Performance verification of CYP2C19 enzyme abundance polymorphism settings within the simcyp simulator v21
C Sychterz, I Gardner, M Chiang, R Rachumallu… - Metabolites, 2022 - mdpi.com
Physiologically based pharmacokinetic (PBPK) modeling has a number of applications,
including assessing drug–drug interactions (DDIs) in polymorphic populations, and should …
including assessing drug–drug interactions (DDIs) in polymorphic populations, and should …
In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates
S Goutelle, L Bourguignon, N Bleyzac, J Berry… - The AAPS journal, 2013 - Springer
We present a unified quantitative approach to predict the in vivo alteration in drug exposure
caused by either cytochrome P450 (CYP) gene polymorphisms or CYP-mediated drug–drug …
caused by either cytochrome P450 (CYP) gene polymorphisms or CYP-mediated drug–drug …
Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes
BH Hellum, Z Hu, OG Nilsen - Basic & clinical pharmacology & …, 2009 - Wiley Online Library
The aim of this study was to evaluate in vitro the dose‐dependent induction potential of six
commonly used trade herbal products on CYP2C19 and CYP2E1 metabolic activities in …
commonly used trade herbal products on CYP2C19 and CYP2E1 metabolic activities in …